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Objective: Differentiating metastatic adenocarcinoma from malig-
nant pleural mesothelioma is often a challenging task. Spliced forms
of CD44, such as exon v6 (CD44v6), have been implicated in tumor
metastasis. We examined the diagnostic performance of soluble (s)
CD44v6 and CD44 standard (sCD44std) as biomarkers for nonme-
sothelioma pleural malignancies in a retrospective series.
Methods: The pleural fluid from 161 patients with pleural effusion
(33 mesotheliomas, 104 nonmesothelioma malignancies, and 24
benign conditions) was analyzed for sCD44v6 and sCD44std levels
using an enzyme-linked immunosorbent assay kit. The ability of
sCD44v6 and sCD44std levels and the sCD44v6/std ratio for dis-
tinguishing mesothelioma from nonmesothelioma malignancy were
examined.
Results: Median pleural fluid concentrations of sCD44v6 but not
sCD44std were significantly higher in patients with nonmesothe-
lioma malignancy (101.5 ng/mL) than in those with mesothelioma
(38 ng/mL, p  0.0001). Fluids from metastatic squamous cell
carcinomas exhibited particularly high sCD44v6 levels (388 ng/
mL). A cutoff value of 100 ng/mL had the highest accuracy for
distinguishing mesothelioma from nonmesothelioma malignancy
(sensitivity 53% and specificity 88%) or metastatic adenocarcinoma
(sensitivity 60% and specificity 88%). An sCD44v6/std ratio of
more than 0.34 discriminated between adenocarcinoma and me-
sothelioma with a sensitivity of 60%, a specificity of 93%, a
likelihood ratio positive of 9.97, and an area under the curve of 0.87
(95% confidence interval: 0.80–0.94).
Conclusions: The pleural fluid sCD44v6/std ratio may be a new
diagnostic marker in the differential diagnosis between primary
mesothelioma and other pleural malignancies. Values greater than
0.34 predict nonmesothelioma malignancy and may be a help in
determining whether an invasive thoracoscopy is necessary.
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Epithelial mesotheliomas can be extremely difficult to dis-tinguish cytohistologically from metastatic involvement
of the pleura. The difficulties in establishing a differential
diagnosis between mesothelioma and pleural metastases are
illustrated by a study of 45 pleural fluid specimens, in which
the interobserver agreement of nine expert pathologists in
discriminating these two entities based on morphologic cri-
teria alone was poor (kappa value of 0.343).1 Therefore,
staining of cell blocks or, preferably, of pleural tissue samples
for a battery of mesothelial and carcinoma markers is often
necessary to make a definitive diagnosis.2
The search for a reliable diagnostic biomarker of me-
sothelioma still continues. Among all reported candidates,
soluble mesothelin, in serum or pleural fluid, has received the
most attention.3 Nevertheless, soluble mesothelin levels can
be elevated in adenocarcinomas that metastasized to the
pleura, particularly from an unknown primary site.4
Overexpression of the multifunctional adhesion mole-
cule CD44 (hyaluronan receptor) and its isoforms has been
found to play a major role in tumor invasion and metastasis.5
The interplay of CD44 with its ligands modulates adhesive-
ness, motility, matrix degradation, proliferation, and cell
survival; these are features that permit a tumor cell to proceed
through all the steps of the metastatic cascade. Because the
metastatic spread of mesothelioma constitutes a rare eventu-
ality in the clinical setting, the measurement of spliced CD44
in the pleural fluid represents an attractive prospect for
labeling a malignant effusion as primary (mesothelioma) or
metastatic. The proteolytic cleavage of the extracellular do-
main of CD44 produces a soluble form (sCD44) that can be
detected in biologic fluids.
The primary goal of this study was to test the
hypothesis that the measurement of sCD44 standard
(sCD44std) and the splice variant v6 (sCD44v6) in pleural
fluid can reliably determine the underlying nature of a
malignant pleural effusion, whether metastatic or not. We
also tested the association between the levels of these
markers and mortality.
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PATIENTS AND METHODS
Patients
In two Spanish university hospitals (Arnau de Vil-
anova, Lleida, and Virgen del Rocio, Sevilla), a pleural fluid
databank on all patients who undergo diagnostic thoracentesis
has been prospectively maintained for the last 15 and 25
years, respectively. All pleural fluid specimens are immedi-
ately processed, coded, and stored in aliquots at 80°C until
assayed. For this study, we used a computer-generated strat-
ified randomization of effusions to select 94 samples from
one biobank and 67 from the other, all collected between
1995 and 2009. This was done to guarantee a proportionate
number of patients among the different etiologies. Neverthe-
less, 75% of the mesothelioma samples were provided by one
center due to the higher prevalence of this neoplasm in the
corresponding geographical area. The hospital ethics commit-
tees of the participant centers approved this study, and pa-
tients signed consent forms for their specimens to be stored
for analysis and future research.
Clinical Diagnosis
Effusions were classified as being malignant on the basis
of cytologic and/or immunohistological features, whereas the
diagnosis of benign effusions depended on well-established
clinical criteria. In particular, the diagnostic method in all me-
sothelioma cases was a thoracoscopic pleural biopsy.
Pleural Fluid Assays
Pleural fluid levels of human sCD44std and sCD44v6
were measured at one center by an enzyme-linked immu-
nosorbent assay (ELISA) according to manufacturer’s in-
structions (Bender MedSystems, Vienna, Austria). These
ELISAs detect all circulating CD44 isoforms comprising the
standard and the sCD44v6 protein sequences, respectively.
All samples were analyzed in duplicate, and each data point
represented the mean of both measurements. The laboratory
personnel who performed the tests were blinded of the clin-
ical diagnoses.
Statistical Analysis
Values are reported as the median with interquartile
range because they were not normally distributed. Mann-
Whitney U test (two groups) or Kruskal-Wallis test (more
than two groups) with a post hoc Bonferroni correction was
used to compare continuous variables. Receiver operating
characteristic (ROC) curves were generated to define the
optimal cutoff values of sCD44v6, sCD44std, and their ratio
to discriminate mesothelioma from either nonmesothelioma
malignancy in general or metastatic adenocarcinoma in par-
ticular, searching for specificity greater than 85%. Likelihood
ratios (LRs) with 95% confidence intervals (CIs) were calcu-
lated for the binary cutoff values identified by ROC analysis.
A Kaplan-Meier analysis evaluated the correlation of
sCD44v6, sCD44std, and their ratio and mortality. Two-sided p
values less than 0.05 were considered statistically significant. All
statistical analyses were conducted with a statistical software
package (SPSS, version 16; SPSS Inc.; Chicago, IL).
RESULTS
Patients Characteristics
The study population comprised 93 men and 68 women
with an overall median (interquartile range) age of 65 years
(51–77 years). Patients were classified into five groups ac-
cording to the cause of the pleural effusion: mesotheliomas
(33 patients), metastatic adenocarcinomas (48 patients), lym-
phomas (39 patients), metastatic squamous cell carcinomas
(17 patients), and benign effusions (24 patients). Table 1
details the underlying etiologies of the patients.
Pleural Fluid Levels of sCD44std and sCD44v6
There were no significant differences of pleural fluid
sCD44std levels among the groups (Table 2). Nevertheless,
the median concentrations of pleural sCD44v6 were signifi-
cantly lower in patients with mesothelioma (38 ng/mL) than
in those with nonmesothelioma malignancies (101.5 ng/mL,
p  0.0001) or benign conditions (64.5 ng/mL, p  0.023).
Similarly, the ratio of pleural fluid sCD44v6 to sCD44std was
lower and reached statistical significance in the mesothelioma
group (0.18), when compared with patients with nonhemato-
logic metastatic tumors (0.5, p 0.0001) (Figure 1). Notably,
squamous cell carcinomas exhibited higher pleural fluid lev-
els of sCD44v6 (388 ng/mL) and higher sCD44v6 to
sCD44std ratios (0.64) than any other cause of pleural effu-
sion (83 ng/mL and 0.25, respectively; all p  0.0001). The
concentrations of sCD44std and sCD44v6 were similar
among the three histologic types of mesothelioma (data not
shown).
TABLE 1. Causes of Pleural Effusion in the Study Population
Diagnosis No. (%)
Mesothelioma 33 (20.5)
Epithelioid 29
Sarcomatoid 2
Biphasic 2
Adenocarcinoma 48 (30)
Lung 18
Breast 17
Unknown primary 8
Miscellaneous 5
Lymphoma 39 (24)
B-cell neoplasms 29
T-cell neoplasms 7
Hodgkin lymphoma 3
Squamous cell carcinoma 17 (10.5)
Lung 13
Miscellaneous 4
Benign effusions 24 (15)
Heart failure 8
Parapneumonics 6
Tuberculosis 3
Miscellaneous 7
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Diagnostic Performance of sCD44v6 and
sCD44v6/std
The thresholds of sCD44v6 and the sCD44v6/std ratio
that best discriminated between mesothelioma and nonme-
sothelioma malignancies in general or adenocarcinoma in
particular were 100 ng/mL and 0.34, respectively, according
to ROC analysis (Tables 3 and 4). The respective areas under
the curve generated from the use of sCD44v6 and sCD44v6/std
for distinguishing mesothelioma from nonmesothelioma malig-
nancy or metastatic adenocarcinoma were 0.80 (95% CI: 0.71–
0.91) and 0.87 (95% CI: 0.80–0.94) (Figure 2). Specifically, a
pleural sCD44v6/std ratio greater than 0.34 had a specificity of
93% and a LR positive of 9.97 in separating metastatic adeno-
carcinoma from pleural mesothelioma.
Association of sCD44 with Patient Survival
A trend toward lower median survival was observed in
patients with mesothelioma with pleural sCD44v6 more than
100 ng/mL or sCD44v6/std more than 0.34 (10 versus 17
months), but it failed to reach statistical significance (p values
of 0.391 and 0.982, respectively). The opposite was true for
patients with metastatic adenocarcinoma, who tended to have
a nonsignificant better survival if they exhibited high concen-
trations of sCD44v6 (28 versus 9 months, p  0.18).
DISCUSSION
In this study, we demonstrated that sCD44v6 was
predominantly detected in the pleural fluid of patients with
nonmesothelioma malignancies and also that the sCD44v6/
std ratio could be a useful marker in the differential diagnosis
of pleural malignancy. In contrast with their diagnostic value,
these parameters had no association with survival regardless
of the tumor type.
CD44 is a polymorphic transmembrane glycoprotein
encoded by a single gene located on chromosome 11, which
participates in a wide variety of cell-cell or cell-matrix
interactions including tumor invasion and metastases. CD44
is expressed on the cell membrane in either the standard form
or as a higher-molecular weight isoform (CD44v). Although
the standard CD44 form is widely distributed, splice variants
are highly restricted in their expression in normal or malig-
nant tissues. Various CD44 isoforms, notably CD44v6, have
gained attention as potential markers of metastasis because
they show differential expression in benign and malignant
cell populations.6
TABLE 2. Median (IQR) sCD44std and sCD44v6 Pleural
Fluid Values in Different Groups
Etiology of Pleural
Effusion
sCD44std,
ng/mL
sCD44v6,
ng/mL sCD44v6/std
Mesothelioma 288 (172–415) 38 (28.5–85.5)a 0.18 (0.12–0.25)b
Nonmesothelioma
malignancy
330 (240–515) 101.5 (74–188.3) 0.35 (0.21–0.59)
Adenocarcinoma 318 (233–417) 123.5 (75–218) 0.43 (0.28–0.62)
Squamous cell
carcinoma
306 (226–755) 388 (118–771)c 0.64 (0.52–1.6)d
Lymphoma 399 (264–789) 86 (70–102) 0.21 (0.12–0.31)
Benign effusions 310 (162–578) 64.5 (56–93) 0.23 (0.13–0.35)
a Significantly lower than the respective values in other malignant effusions (p 
0.0001) and the benign group (p  0.02) by post hoc test.
b Significantly lower than the respective values in nonmesothelioma malignancy
(p  0.001), adenocarcinoma, and squamous cell carcinoma groups (p  0.0001).
c Significantly higher than the respective values in other groups by post hoc test (p 
0.005).
d Significantly higher than the respective values in other groups by post hoc test (p 
0.005).
IQR, interquartile range.
FIGURE 1. Box plots of pleural fluid
sCD44v6/std ratios in different
etiologies of pleural effusion. The
sCD44v6/std ratio was significantly
lower in mesotheliomas than in ade-
nocarcinomas and squamous cell
carcinomas (p  0.0001).
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A few pilot studies have proposed the analysis of CD44
isoforms on cell blocks from pleural effusions as an aid in the
differential diagnosis between benign and malignant conditions.
For example, Okamoto et al.7 developed a competitive reverse-
transcription polymerase chain reaction that allowed the detec-
tion of cancer cells overexpressing CD44v8-10 in pleural fluids.
A v8-10/v10 ratio greater than 1 differentiated 41 carcinomatous
effusions from 34 benign effusions with a sensitivity of 76%, a
specificity of 94%, an LR positive of 12.85 and an LR negative
of 0.26. Using a similar methodology, Tojo et al.8 demonstrated
expression of CD44v7 in 16 of 17 carcinomatous pleural effu-
sions but in only 2 of 10 benign effusions. Notably, CD44v6 was
equally expressed in both malignant and benign conditions.
Other techniques, such as immunohistochemistry on pleural
fluid cells with anti-CD44std/v specific antibodies, have dem-
onstrated membranous immunostaining for CD44 isoforms in a
variable proportion of reactive mesothelial (benign) and adeno-
carcinoma cells.9 For example, in one study of 23 benign
effusions (19 peritoneal and 4 pleural) and 45 metastatic adeno-
carcinoma effusions (29 ascites and 16 pleural fluids), benign
mesothelial cells expressed CD44std in 96% and CD44v6 in 4%
of the cases, whereas none stained for CD44v3-10.10 In contr-
ast, there was immunoreactivity for CD44std, CD44v6, and
CD44v3-10 in 24%, 47%, and 87% of malignant effusions,
respectively. The authors concluded that identification of
CD44std pointed to a reactive mesothelial cell origin,
whereas CD44v3-10 immunoreactivity supported the diagno-
sis of adenocarcinoma.10 Finally, Afify et al.11 tested an
instant ELISA for sCD44v6 (as in this study) on the cell-free
supernatant fluids from 10 benign effusions (eight pleural and
two ascitis specimens) and 20 malignant effusions (11 pleural
and nine ascitic samples) but did not include mesotheliomas.
Levels of sCD44v6 exceeding 27 ng/mL had 90% sensitivity,
70% specificity, an LR positive of 3, and an LR negative of
0.14 for identifying the malignant fluids. For the present
investigation, we scrutinized only those sCD44 ELISA kits
that are commercially available, thus searching for their
potential applicability in clinical practice.
Our study focused on the distinction between mesothe-
lioma and adenocarcinoma rather than benign-malignant dif-
ferentiation. In a recent international consensus statement,
neither CD44std nor any CD44 isoforms were included in the
immunohistochemical panels recommended for the patho-
logic diagnosis of malignant mesothelioma,2 likely due to the
small number of studies.12–14 Malignant pleural mesotheli-
oma cells may have morphologic characteristics that may
cause them to be diagnosed as metastases of carcinoma. A
conclusive diagnosis often requires a sufficient quantity of
pleural tissue, usually obtained through thoracoscopy, to
allow for immunohistochemical characterization. The find-
ings of this study suggest that the probability of metastatic
adenocarcinoma in a patient with positive compatible fluid
cytology and pleural sCD44v6/std more than 0.34 is suffi-
TABLE 3. Diagnostic Accuracy of Pleural sCD44v6 and sCD44v6/std Ratio for Identifying
Nonmesothelioma Malignancy Against Mesothelioma
Parameter
Sensitivity,
% (95% CI)
Specificity,
% (95% CI) LR (95% CI) LR (95% CI)
Pleural sCD44v6 100 ng/mL 52 (43–62) 87 (76–99) 4.36 (1.71–11.12) 0.54 (0.42–0.69)
sCD44v6/std 0.34 50 (40–59) 93 (85–100) 8.25 (2.12–32.05) 0.53 (0.43–0.65)
LR, likelihood ratio; CI, confidence interval.
TABLE 4. Diagnostic Accuracy of Pleural sCD44v6 and sCD44v6/std Ratio for Identifying
Adenocarcinoma vs. Mesothelioma
Parameter
Sensitivity,
% (95% CI)
Specificity,
% (95% CI) LR (95% CI) LR (95% CI)
Pleural sCD44v6 100 ng/mL 60 (46–74) 87 (76–99) 4.98 (1.93–12.84) 0.45 (0.31–0.65)
sCD44v6/std 0.34 60 (46–74) 93 (85–100) 9.97 (2.55–38.95) 0.42 (0.29–0.60)
LR, likelihood ratio; CI, confidence interval.
FIGURE 2. Receiver operating characteristic (ROC) curve of
pleural fluid sCD44v6/std ratio for differentiating adenocarci-
noma from mesothelioma. The area under the curve (AUC)
value was 0.87 (95% confidence interval [CI]: 0.80–0.94).
Journal of Thoracic Oncology • Volume 6, Number 1, January 2011 Use of Pleural Fluid sCD44v6/std Ratio
Copyright © 2010 by the International Association for the Study of Lung Cancer 193
ciently high (LR  10), so that thoracoscopy for tissue
confirmation may be considered unnecessary on an individual
basis. Nevertheless, a pleural sCD44v6/std ratio less than
0.34 does not reduce probability adequately, so as to be
clinically meaningful (LR  0.4). Thus, in the latter situ-
ation, the ratio is not recommended for use in making a
definitive diagnosis of mesothelioma versus adenocarcinoma.
It should be stressed that sCD44 test results should not be
substituted for clinical judgment to determine whether a
diagnostic thoracoscopy is necessary in the preceding clinical
scenario. Other factors, such as a history of asbestos exposure
or the presence of certain radiologic features (e.g., diffuse
pleural thickening or mass with thickening of interlobular
fissures on CT scan), may influence the final decision, re-
gardless of the pleural sCD44v6/std ratio.
This study has some limitations. Our findings, which
are based on retrospective analysis, deserve further prospec-
tive evaluation in an independent validation cohort. How the
new tests perform in a subgroup of patients where the
cytologic results are uncertain (mesothelioma versus adeno-
carcinoma) or contain false negatives (malignancy), rather
than in well-defined populations, remains to be determined.
Finally, although the sCD44v6/std ratio may be helpful in
differential diagnosis, histology remains the gold standard.
In conclusion, this study shows that measurement of
sCD44v6/std could be a helpful adjunct for the differential
diagnosis of malignant pleural effusions, allowing the iden-
tification of those with a high probability of being metastatic
and, therefore, precluding the indication of an invasive tho-
racoscopy in the adequate clinical setting.
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